Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine in anaplastic large cell lymphoma

Biochimie

Volumn 94, Issue 11, 2012, Pages 2297-2307

  Hassler, Melanie R ^a   Klisaroska, Aleksandra ^a   Kollmann, Karoline ^b   Steiner, Irene ^a   Bilban, Martin ^a   Schiefer, Ana Iris ^a   Sexl, Veronika ^b   Egger, Gerda ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

5 Aza 2 deoxycytidine; Anaplastic large cell lymphoma; Decitabine; DNA methyltransferase inhibitor; NPM ALK; T cell lymphoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BETA GALACTOSIDASE; CD30 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; DRUG SCREENING; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PROMOTER REGION; SENESCENCE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MICE; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867405061     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2012.05.029     Document Type: Article

References (58)

1. R. Holliday, and J.E. Pugh DNA modification mechanisms and gene activity during development Science 187 1975 226 232
2. P.A. Jones, and S.B. Baylin The fundamental role of epigenetic events in cancer Nat. Rev. Genet. 3 2002 415 428
3. G. Egger, G. Liang, A. Aparicio, and P.A. Jones Epigenetics in human disease and prospects for epigenetic therapy Nature 429 2004 457 463
4. C.B. Yoo, and P.A. Jones Epigenetic therapy of cancer: past, present and future Nat. Rev. Drug Discov. 5 2006 37 50
5. D.V. Santi, C.E. Garrett, and P.J. Barr On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs Cell 33 1983 9 10
6. D.V. Santi, A. Norment, and C.E. Garrett Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine Proc. Natl. Acad. Sci. U S A 81 1984 6993 6997
7. H.M. Kantarjian, and J.P. Issa Decitabine dosing schedules Semin. Hematol. 42 2005 S17 S22
8. E. Kaminskas, A. Farrell, S. Abraham, A. Baird, L.S. Hsieh, S.L. Lee, J.K. Leighton, H. Patel, A. Rahman, R. Sridhara, Y.C. Wang, and R. Pazdur Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes Clin. Cancer Res. 11 2005 3604 3608
9. J.P. Issa, G. Garcia-Manero, F.J. Giles, R. Mannari, D. Thomas, S. Faderl, E. Bayar, J. Lyons, C.S. Rosenfeld, J. Cortes, and H.M. Kantarjian Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 2004 1635 1640
10. J.M. Scandura, G.J. Roboz, M. Moh, E. Morawa, F. Brenet, J.R. Bose, L. Villegas, U.S. Gergis, S.A. Mayer, C.M. Ippoliti, T.J. Curcio, E.K. Ritchie, and E.J. Feldman Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML Blood 118 2011 1472 1480
11. Y. Boumber, and J.P. Issa Epigenetics in cancer: what's the future? Oncol. (Williston Park) 25 2011 220 226 228
12. M.C. Kinney, R.A. Higgins, and E.A. Medina Anaplastic large cell lymphoma: twenty-five years of discovery Arch. Pathol. Lab. Med. 135 2011 19 43
13. Y. Kaneko, G. Frizzera, S. Edamura, N. Maseki, M. Sakurai, Y. Komada, H. Tanaka, M. Sasaki, and T. Suchi A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis Blood 73 1989 806 813
14. M.M. Le Beau, M.A. Bitter, R.A. Larson, L.A. Doane, E.D. Ellis, W.A. Franklin, C.M. Rubin, M.E. Kadin, and J.W. Vardiman The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma Leukemia 3 1989 866 870
15. R. Rimokh, J.P. Magaud, F. Berger, J. Samarut, B. Coiffier, D. Germain, and D.Y. Mason A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma') Br. J. Haematol. 71 1989 31 36
16. H.M. Amin, and R. Lai Pathobiology of ALK+anaplastic large-cell lymphoma Blood 110 2007 2259 2267
17. R. Chiarle, C. Voena, C. Ambrogio, R. Piva, and G. Inghirami The anaplastic lymphoma kinase in the pathogenesis of cancer Nat. Rev. Cancer 8 2008 11 23
18. R.H. Palmer, E. Vernersson, C. Grabbe, and B. Hallberg Anaplastic lymphoma kinase: signalling in development and disease Biochem. J. 420 2009 345 361
19. T. Nagasawa, Q. Zhang, P.N. Raghunath, H.Y. Wong, M. El-Salem, A. Szallasi, M. Marzec, P. Gimotty, A.H. Rook, E.C. Vonderheid, N. Odum, and M.A. Wasik Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing Leuk. Res. 30 2006 303 312
20. C. Ambrogio, C. Martinengo, C. Voena, F. Tondat, L. Riera, P.F. di Celle, G. Inghirami, and R. Chiarle NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells Cancer Res. 69 2009 8611 8619
21. J.D. Khoury, G.Z. Rassidakis, L.J. Medeiros, H.M. Amin, and R. Lai Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma Blood 104 2004 1580 1581
22. Q. Zhang, H.Y. Wang, G. Bhutani, X. Liu, M. Paessler, J.W. Tobias, D. Baldwin, K. Swaminathan, M.C. Milone, and M.A. Wasik Lack of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+TCL) cells from apoptosis Proc. Natl. Acad. Sci. U S A 106 2009 15843 15848
23. A. Akimzhanov, L. Krenacs, T. Schlegel, S. Klein-Hessling, E. Bagdi, E. Stelkovics, E. Kondo, S. Chuvpilo, P. Wilke, A. Avots, S. Gattenlohner, H.K. Muller-Hermelink, A. Palmetshofer, and E. Serfling Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling Am. J. Pathol. 172 2008 215 224
24. Q. Zhang, H.Y. Wang, A. Woetmann, P.N. Raghunath, N. Odum, and M.A. Wasik STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes Blood 108 2006 1058 1064
25. M.C. Le Deley, A. Reiter, D. Williams, G. Delsol, I. Oschlies, K. McCarthy, M. Zimmermann, and L. Brugieres Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study Blood 111 2008 1560 1566
26. L. Gautier, L. Cope, B.M. Bolstad, and R.A. Irizarry Affy-analysis of Affymetrix GeneChip data at the probe level Bioinformatics 20 2004 307 315
27. G.K. Smyth Linear models and empirical bayes methods for assessing differential expression in microarray experiments Stat. Appl. Genet. Mol. Biol. 3 2004 Article3
28. R.C. Gentleman, V.J. Carey, D.M. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis, L. Gautier, Y. Ge, J. Gentry, K. Hornik, T. Hothorn, W. Huber, S. Iacus, R. Irizarry, F. Leisch, C. Li, M. Maechler, A.J. Rossini, G. Sawitzki, C. Smith, G. Smyth, L. Tierney, J.Y. Yang, and J. Zhang Bioconductor: open software development for computational biology and bioinformatics Genome Biol. 5 2004 R80
29. D. Gius, H. Cui, C.M. Bradbury, J. Cook, D.K. Smart, S. Zhao, L. Young, S.A. Brandenburg, Y. Hu, K.S. Bisht, A.S. Ho, D. Mattson, L. Sun, P.J. Munson, E.Y. Chuang, J.B. Mitchell, and A.P. Feinberg Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach Cancer Cell 6 2004 361 371
30. H. Caren, A. Djos, M. Nethander, R.M. Sjoberg, P. Kogner, C. Enstrom, S. Nilsson, and T. Martinsson Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma BMC Cancer 11 2011 66
31. R. Jaenisch, and A. Bird Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals Nat. Genet. 33 2003 245 254
32. T. Chen, S. Hevi, F. Gay, N. Tsujimoto, T. He, B. Zhang, Y. Ueda, and E. Li Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells Nat. Genet. 39 2007 391 396
33. G. Egger, S. Jeong, S.G. Escobar, C.C. Cortez, T.W. Li, Y. Saito, C.B. Yoo, P.A. Jones, and G. Liang Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival Proc. Natl. Acad. Sci. U S A 103 2006 14080 14085
34. P.W. Hollenbach, A.N. Nguyen, H. Brady, M. Williams, Y. Ning, N. Richard, L. Krushel, S.L. Aukerman, C. Heise, and K.J. MacBeth A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines PLoS One 5 2010 e9001
35. P.A. Jones, and S.M. Taylor Cellular differentiation, cytidine analogs and DNA methylation Cell 20 1980 85 93
36. S.M. Taylor, and P.A. Jones Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine Cell 17 1979 771 779
37. P. Martinelli, P. Bonetti, C. Sironi, G. Pruneri, C. Fumagalli, P.R. Raviele, S. Volorio, S. Pileri, R. Chiarle, F.K. McDuff, B.K. Tusi, S.D. Turner, G. Inghirami, P.G. Pelicci, and E. Colombo The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway Blood 117 2011 6617 6626
38. M. Almstedt, N. Blagitko-Dorfs, J. Duque-Afonso, J. Karbach, D. Pfeifer, E. Jager, and M. Lubbert The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells Leuk. Res. 34 2010 899 905
39. H.M. Kantarjian, S. O'Brien, J. Cortes, F.J. Giles, S. Faderl, J.P. Issa, G. Garcia-Manero, M.B. Rios, J. Shan, M. Andreeff, M. Keating, and M. Talpaz Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia Cancer 98 2003 522 528
40. Y. Oki, H.M. Kantarjian, V. Gharibyan, D. Jones, S. O'Brien, S. Verstovsek, J. Cortes, G.M. Morris, G. Garcia-Manero, and J.P. Issa Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia Cancer 109 2007 899 906
41. W. Blum, R.B. Klisovic, B. Hackanson, Z. Liu, S. Liu, H. Devine, T. Vukosavljevic, L. Huynh, G. Lozanski, C. Kefauver, C. Plass, S.M. Devine, N.A. Heerema, A. Murgo, K.K. Chan, M.R. Grever, J.C. Byrd, and G. Marcucci Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia J. Clin. Oncol. 25 2007 3884 3891
42. A.F. Cashen, A.K. Shah, L. Todt, N. Fisher, and J. DiPersio Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Cancer Chemother. Pharmacol. 61 2008 759 766
43. D.M. Hellebrekers, K.W. Jair, E. Vire, S. Eguchi, N.T. Hoebers, M.F. Fraga, M. Esteller, F. Fuks, S.B. Baylin, M. van Engeland, and A.W. Griffioen Angiostatic activity of DNA methyltransferase inhibitors Mol. Cancer Ther. 5 2006 467 475
44. R. Halaban, M. Krauthammer, M. Pelizzola, E. Cheng, D. Kovacs, M. Sznol, S. Ariyan, D. Narayan, A. Bacchiocchi, A. Molinaro, Y. Kluger, M. Deng, N. Tran, W. Zhang, M. Picardo, and J.J. Enghild Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications PLoS One 4 2009 e4563
45. M. Kasprzycka, M. Marzec, X. Liu, Q. Zhang, and M.A. Wasik Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3 Proc. Natl. Acad. Sci. U S A 103 2006 9964 9969
46. D. Atanackovic, T. Luetkens, B. Kloth, G. Fuchs, Y. Cao, Y. Hildebrandt, S. Meyer, K. Bartels, H. Reinhard, N. Lajmi, S. Hegewisch-Becker, G. Schilling, U. Platzbecker, G. Kobbe, T. Schroeder, C. Bokemeyer, and N. Kroger Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia Am. J. Hematol. 86 2011 918 922
47. R. Claus, M. Almstedt, and M. Lubbert Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents Semin. Oncol. 32 2005 511 520
48. C. Stresemann, and F. Lyko Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine Int. J. Cancer 123 2008 8 13
49. Q. Zhang, H.Y. Wang, M. Marzec, P.N. Raghunath, T. Nagasawa, and M.A. Wasik STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes Proc. Natl. Acad. Sci. U S A 102 2005 6948 6953
50. Q. Zhang, H.Y. Wang, X. Liu, and M.A. Wasik STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression Nat. Med. 13 2007 1341 1348
51. Q. Zhang, H.Y. Wang, X. Liu, G. Bhutani, K. Kantekure, and M. Wasik IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK Proc. Natl. Acad. Sci. U S A 108 2011 11977 11982
52. M. Marzec, M. Kasprzycka, A. Ptasznik, P. Wlodarski, Q. Zhang, N. Odum, and M.A. Wasik Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3 Lab. Invest. 85 2005 1544 1554
53. W. Wan, M.S. Albom, L. Lu, M.R. Quail, N.C. Becknell, L.R. Weinberg, D.R. Reddy, B.P. Holskin, T.S. Angeles, T.L. Underiner, S.L. Meyer, R.L. Hudkins, B.D. Dorsey, M.A. Ator, B.A. Ruggeri, and M. Cheng Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells Blood 107 2006 1617 1623
54. A.V. Galkin, J.S. Melnick, S. Kim, T.L. Hood, N. Li, L. Li, G. Xia, R. Steensma, G. Chopiuk, J. Jiang, Y. Wan, P. Ding, Y. Liu, F. Sun, P.G. Schultz, N.S. Gray, and M. Warmuth Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK Proc. Natl. Acad. Sci. U S A 104 2007 270 275
55. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, S. Fanning, J. Zimmermann, and N.B. Lydon Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat. Med. 2 1996 561 566
56. O. Merkel, F. Hamacher, E. Sifft, L. Kenner, and R. Greil Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools Mol. Cancer Ther. 10 2011 1127 1136
57. S. Roychowdhury, and M. Talpaz Managing resistance in chronic myeloid leukemia Blood Rev. 25 2011 279 290
58. A.M. Eiring, J.S. Khorashad, K. Morley, and M.W. Deininger Advances in the treatment of chronic myeloid leukemia BMC Med. 9 2011 99